• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.

作者信息

Basile Jan, Houston Mark, Ferrario Carlos M

机构信息

Ralph H. Johnson VA Medical Center and Division of General Internal Medicine/Geriatrics, Medical University of South Carolina, Charleston, SC 29401, USA.

出版信息

J Cardiometab Syndr. 2006 Fall;1(5):358-61. doi: 10.1111/j.1559-4564.2006.06035.x.

DOI:10.1111/j.1559-4564.2006.06035.x
PMID:17679795
Abstract
摘要

相似文献

1
Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.治疗心脏代谢综合征：提供全面降低心血管风险的契机。
J Cardiometab Syndr. 2006 Fall;1(5):358-61. doi: 10.1111/j.1559-4564.2006.06035.x.
2
Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.2型糖尿病患者心血管风险的管理作为心脏代谢综合征的一个组成部分。
J Cardiometab Syndr. 2006 Spring;1(2):133-40. doi: 10.1111/j.1559-4564.2006.05487.x.
3
EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.欧洲动脉粥样硬化研究项目III。全科医疗中无症状高危患者心血管危险因素的管理：12个欧洲国家的横断面调查。
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):530-40. doi: 10.1097/HJR.0b013e3283383f30.
4
Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.奠基人群中心血管危险因素及亚临床血管病变的年龄和性别特异性知晓、治疗与控制：撒丁岛研究（SardiNIA研究）
Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):532-41. doi: 10.1016/j.numecd.2008.11.004. Epub 2009 Mar 25.
5
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).欧洲临床实践中心血管疾病预防指南：全文。欧洲心脏病学会及其他学会关于临床实践中心血管疾病预防的第四联合工作组（由九个学会的代表及特邀专家组成）。
Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113. doi: 10.1097/01.hjr.0000277983.23934.c9.
6
Management of hypertension in children and adolescents with the metabolic syndrome.患有代谢综合征的儿童和青少年的高血压管理。
J Cardiometab Syndr. 2006 Summer;1(4):259-68. doi: 10.1111/j.1559-4564.2006.05801.x.
7
Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.索尔维致力于满足患有心脏代谢和脂质紊乱的高血压患者在管理方面未得到满足的需求。
Cardiovasc J Afr. 2009 Jan-Feb;20(1):73-4.
8
Prehypertension and the cardiometabolic syndrome: is there any value in pharmacologic intervention?高血压前期与心脏代谢综合征：药物干预是否有价值？
J Cardiometab Syndr. 2006 Spring;1(2):146-8. doi: 10.1111/j.1559-4564.2006.05527.x.
9
Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".关于“外周动脉疾病的药理学危险因素管理：血管外科医生手册”。
J Vasc Surg. 2008 Sep;48(3):776-7; author reply 777. doi: 10.1016/j.jvs.2008.04.074.
10
Present recommendations in type 2 diabetes treatment.2型糖尿病治疗的现有建议。
Endocrinol Nutr. 2009 Dec;56 Suppl 4:46-9.

引用本文的文献

1
Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?“裸体皇帝”比喻是否适用于当前人们对肾素-血管紧张素系统抑制在高血压中作用的看法？
Curr Hypertens Rep. 2022 Dec;24(12):709-721. doi: 10.1007/s11906-022-01229-x. Epub 2022 Oct 22.
2
Meta-Analysis of the Effects of Foods and Derived Products Containing Ellagitannins and Anthocyanins on Cardiometabolic Biomarkers: Analysis of Factors Influencing Variability of the Individual Responses.鞣花单宁和花色苷类食物及其衍生产品对心血管代谢生物标志物影响的荟萃分析：个体反应差异影响因素分析。
Int J Mol Sci. 2018 Feb 28;19(3):694. doi: 10.3390/ijms19030694.
3
Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.
固定剂量复方制剂在高血压治疗中的临床应用：奈必洛尔/缬沙坦联用潜力的证据
Integr Blood Press Control. 2014 Nov 26;7:61-70. doi: 10.2147/IBPC.S50954. eCollection 2014.
4
Impact of performance improvement continuing medical education on cardiometabolic risk factor control: the COSEHC initiative.绩效改进继续医学教育对心脏代谢危险因素控制的影响：COSEHC倡议
J Contin Educ Health Prof. 2014 Winter;34(1):25-36. doi: 10.1002/chp.21217.